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Abstract
Introduction: The article deals with to the new approaches to the immunotherapy of chronic cystitis. Cystitis appears 
to be a disease linked to the decreased immunity of the population. 
Materials and Methods: The study included 200 patients with chronic cystitis, and was performed in three stages. At 
the first stage, all 200 patients were questioned to determine whether they do or do not have the basic immunopatholog-
ical syndromes. At the second stage, the patients of 6 clinical groups underwent a routine immunologic examination us-
ing tests to evaluate basic populations, lymphocyte subpopulations, immune globulins, circulating immune complexes, 
average weight molecules, absorbing and metabolic phagocytic ability, pro- and anti-inflammatory cytokines by using 
flow cytofluorometry methods. The third stage included distribution of the major group of patients with chronic cystitis 
in the relapse stage into subgroups of 25 patients each who received conventional therapy. 
Results and Discussion: The study has the following findings: the formation of risk groups depends on immuno-
pathological syndromes and clinical-laboratory markers of disease peculiarities; signal tests of immunologic disorders 
and their correlative links with metabolic stress parameters were specified and formalized as diagnostic formulas; 
high clinical-bacteriological and low hemato-immunological efficacy of the conventional therapy patients with chronic 
cystitis and the capacity of the local and systemic modulators, such as kipferon, superlimf and imunofan, galavit, and 
their combinations, to normalize the  parameters under study during 7-10 days were demonstrated. When combining 
the correctors, it was possible to achieve new quality independent of the properties of individual agents included in the 
composition; the reveal targets of various immune therapies were conditioned by the treatment provided, the character-
istics of the correctors, the identification period – 7-10 days – 3-4 months. The analysis of the formulas of modulator 
targets made it possible to identify laboratory findings for their selection. 
Conclusion: The data obtained during the study support the fact that there was no clinical efficacy of the conventional 
therapy for patients; this efficacy was maintained through to the  administration of the combination of modulators in 
the acute period.  Substantiated differentiated immunotherapy resulted in implementing the proper algorithm of obser-
vations, which prevented recurring of chronic cystitis in 3-4 months. 
Keywords
immunomodulators, immunopathological syndrome, clinical-laboratory markers, conventional pharmacotherapy
Introduction
The incidence of cystitis has increased recently (Hauser 
et al. 2016). This appears to be related to the decreased 
collective immunity of humankind, changes in the de-
mographic situation resulting in an increased shyare of 
senior citizens in the population, including women in the 
climacteric period, and insufficient efficacy of the con-
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ventional antibacterial therapy ignoring immunologic di-
sorders in patients (Zemskov et al. 2016).
A certain research design algorithm was developed to 
obtain the study objectives: to increase the efficacy of 
the traditional cystitis therapy through valid differentiated 
immunotherapy.
Materials and methods
The plan of clinical research was presented at the meeting 
of the Ethics Committee of Voronezh N.N. Burdenko Sta-
te Medical University of the Ministry of Healthcare of the 
Russian Federation and in compliance with the provisions 
of the Declaration of Helsinki on medical ethics.
The study included 200 patients with chronic cystitis in 
the relapse stage (group 1), 24 patients with acute cystitis 
(group 2), 20 patients with chronic cystitis in the relap-
se stage combined with chronic pyelonephritis (group 3), 
and 22 patients with chronic cystitis in the relapse stage 
combined with chronic salpingo-oophoritis in the relapse 
stage (group 4). A group of comparison included 30 healt-
hy people of similar age. All the patients participating in 
the study were diagnosed using conventional methods. 
At the first stage of the study, using pre-laboratory me-
thods, all the 266 patients were interviewed to reveal pre-
sence or absence of basic immunopathological syndromes 
– immunodeficient, infectious, allergic, autoimmune, and 
lymphoproliferative (Zemskov et al. 2013). The patients 
withut any syndrome were included in the no-risk group; 
the patients with one of these syndromes were included in 
the risk group; the patients with a combination of syndro-
me were included in the group of increased risk (Zemskov 
et al. 2017).
At the second stage, the patients of 6 clinical groups 
underwent a routine immunologic examination using 26 
tests to evaluate basic populations, lymphocyte subpo-
pulations, immune globulins, circulating immune com-
plexes, average weight molecules, absorbing and me-
tabolic phagocytic ability, pro- and anti-inflammatory 
cytokines by flow cytofluorometry methods. In the ob-
tained body of data, cellular, humoral, phagocytic, cytoki-
ne reactions were assessed by means of the rank-ordering 
method depending on what component of the immune 
system the indicators refer to. Signal tests of disorders 
were selected using the coefficient of diagnostic conside-
rations (Bollestad et al. 2018).
At the third stage, the main group of patients – group 
1 – was categorized into 6 subgroups, 25 people each; 
they were given conventional therapy: with monural, flu-
oroquinolones, semisynthetic antibiotics with urogenous 
septics (nitrofurantoin, furaginum), symptomatic medica-
tions, etc. Kipferon (Kf), superlimf (Sl), imunofan (If), 
galavit (Gl) and the combination superlimf+imunofan 
(Sl+If) were used as local and systemic modulators.
Prior to the therapy and 7-10 days after the treatment 
onset, the incidence of the following parameters was de-
termined in patients:
– clinical symptoms of the urinary syndrome – fre-
quent urination, urge urinary incontinence, cloudy 
urine, foul-smelling urine, leukocyturia, terminal 
hematuria;
– intoxication syndrome – lower abdominal pains, 
subfebrile condition, intoxication;
– bacteriologic indices – bacteriuria, E. coli isolated 
from the urine, unidentified gram-negative micro-
flora (GN), sterile urine samples;
– modified routine hematologic markers of inflamma-
tion;
– immunologic parameters.
In 20 patients receiving conventional therapy and in 
20 patients receiving conventional therapy in combinati-
on with superlimf+imunofan, the above-mentioned tests 
were done again 3-4 months later.
In addition, the metabolic status was assessed in 20 
patients of group 1 (chronic cystitis in the relapse stage): 
parameters of free-radical lipid and protein oxidation 
(FRO), antioxidant defense (AOD) - diene conjugates 
(DC), ketodienes (KD), malondialdehydes (MDA), bi-ty-
rosine cross-links (BC). Super oxide dismutase (SOD), 
catalase (C), vitamin E (VE), systemic thiols (ST) were 
detected in the AOD system. 
Mathematic analysis of the obtained data
At the stage of the study design, the patients’ groups and 
subgroups were randomized according to their gender, 
age, severity of the disease on the basis of random normal 
numbers and the representativeness of sample using the 
formula by L.E. Kholodova and V.P. Yakovleva. (Zemsk-
ov et al. 2008).
Several types of rank formalized assessment of the va-
riations of 9 clinical, 4 bacteriologic, 5 hematologic and 
26 immunologic findings grouped depending on certain 
associations were used to measure comparative efficacy 
of the differentiated immunotherapy of chronic cystitis in 
the relapse stage. The analysis was made on: a mobile ef-
fect characterized by the proportion of parameters which 
had significantly changed compared to the initial level, a 
normalizing action compared to the normative parameters 
in healthy people from the comparison group, diviation 
from the efficacy of one type of conventional treatment, 
a mean percentage of diviation from the norm in patients 
categorized by methods of examination. An integral eva-
luation was performed in ranks on the following scale: in-
significant (rank 3) – when the parameter had significantly 
changed in 0-33% of the patients, mean (rank 2) – when 
the parameter had significantly changed in 34-66% of the 
patients, significant (rank 1) – when the parameter had sig-
nificantly changed in more than 66% of the patients.
Signal tests of disorders were selected using the coef-
ficient of diagnostic considerations calculated by the for-
mula (Gorelik and Skripkin 1974):
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where δ1 and δ2 were mean square deviations, М1, 
М2 were mean parameters of the compared groups. The 
signal tests of disorders were selected with the following 
interpretation: the less was Kj module, the higher was the 
level of diviations from the determined level. 
Signal parameters were formalized in typical formulas: 
the formula of the immune system disorders (FISD) cal-
culated in relation to the normative parameters in healthy 
people; the formula of targets of immunocorrection (FTI) 
which were calculated in relation to the initial parame-
ters; the formula of “proper” targets of immunocorrection 
(FTIprop) calculated in relation to the conventional therapy.
Optimality of the immune system reaction was indi-
rectly characterized by the definition of intra-, inter-, ex-
trasystemic strong correlative links with the coefficient > 
0.6 of pivotal parameters of FISD (Zemskov et al. 2017)
By means of the inversive backward analysis of the 
composition of FTI, the laboratory markers were defined 
for selecting medications (Gevorkyan 2017)
Results and discussion
Clinical laboratory markers of risk groups of im-
munopathological syndromes in patients suffering 
from chronic cystitis
The results of the interview demonstrated that, out of 200 
patients suffering from chronic cystitis in the relapse stage 
(group 1), 26 patients (13%) were included in the no-risk 
groups, 156 patients (78%) belonged to the risk group, 18 
patients (9%) were included in the increased risk group. 
Out of 24 patients suffering from acute cystitis (group 2), 
18 patients (75%) were in the risk group, and 19 patients 
(95%) of group 3 (20 patients suffering from chronic cysti-
tis combined with chronic pyelonephritis) and 21 patients 
(95%) of group 4 (22 patients suffering from chronic cys-
titis combined with chronic salpingo-oophoritis) were in 
the increased risk group – the combination of the infec-
tious syndrome with immunodeficient or allergic syndro-
me. Moreover, modifications in ranks were expressed to a 
minimum degree in patients of the no-risk group suffering 
from chronic cystitis in the relapse stage; modifications in 
ranks were expressed to an average degree in patients of 
the risk group suffering from chronic cystitis in the relapse 
stage; modifications in ranks were expressed to a large ex-
tent in patients of the increased risk group suffering from 
chronic cystitis in the relapse stage. The groups of patients 
intended for the complex examination were selected after 
determining the representativeness (Tables 1-3).
Table 1 demonstrated that proportion of the detecti-
on of basic clinical symptoms in patients of the no-risk, 
risk and increased risk groups ranged from 19, 30, 33% 
to 100%. Patients mostly manifested frequent urination, 
lower abdominal pains, cloudy urine with foul smell (84-
100% of cases) and leukocyturia (in 58-72% of cases). 
The dynamics of the bacteriologic findings (bacteriu-
ria, E. coli culturing) in patients of three immunopatho-
logic groups were equally extremely high (62-91%) and 
frequency of sterile samples was correspondingly low (6-
9%).
The variations of hematologic inflammation markers 
by mean values were monotonous, but their frequen-
cy-response analysis revealed some peculiarities. Thus, 
the number of unchanged laboratory findings amounted to 
67% in the patients of the no-risk group, 56% – in patients 
of the risk group, 33% – in patients of the increased risk 
group (Р<0.05 for the latter group). 
Identifying the signal tests summarized in FISD marked 
a qualitatively different nature of the laboratory findings. 
Hyperimmunoglobulinemia M combined with inhibition 
of phagocyte operative oxygen activity in the presence 
of T cells deficiency of the II-III degree was common in 
patients of the no-risk group - IgM+3 NBTspont-2 Т-2;IgA 
deficiency, excessive IL-6 content of the maximal and 
moderate intensity was observed in patients of the risk 
group - Tcytotoxic+3 IgA-2 IL6+2. The formula NKcytotoxic+3 
Tcytotoxic+3 Thelpers+3 confirmed the limited stimulation of the 
number of cytotoxic natural killers and lymphocytes and 
Thelpers in patients of the increased risk group. 
In addition to the abovementioned, the clinical stage of 
cystitis – primarily acute, secondary recurrent, its combi-
nations with chronic pyelonephritis or salpingo-oophoritis 
– had an impact on the development of immunopatholo-
gical syndromes and peculiarities of laboratory variations 
of patients’ reactivity (Ditkoff et al. 2018, Gyaurgiyev et 
al. 2015).
Therefore, the pre-laboratory identification of risk 
groups based on the presence of immunopathological 
syndromes in case of cystitis can be considered as an 
indirect method of assessing anti-infectious resistance 
without any specific examination of patients (Bove et al. 
2018, Cruz 2014, Jung et al. 2018).
Peculiarities of metabolic status in patients with chro-
nic cystitis
An acute phase of chronic cystitis was found to be charac-
terized by a valid increase of DC concentration from 
34.6+-1.83 to 36.52+-1,47; KD – from 19.62+-0.77 to 
25.01+-2.11; MDA – from 1.36+-0.06 to 1.7+-0.08 and 
BC – from 0.3+-0.012 to 0.37+-0.006. At the same time, 
the initial content of SOD and C was significantly stimu-
lated from 1.14+=0.038 and 31.1+-1.43 to 1.0+-0,02 and 
28,0+-0,9, which correlated with accumulation of vitamin 
E from 23.86+-0.71 to 15.8+-0.6 mcm/L and ST – from 
44.52+-0.85 to 34.28+-28.7 mM/L. These findings prove 
the disrupting of the balance of the immune-aggressive 
factors – primary, secondary FRO products and enzyma-
tic, non-enzymatic links of AOD.
Clinical laboratory effiacy of local and systemic immu-
notherapy of chronic cystitis in 7-10 days
The data obtained were summarized in Table 4. For dis-
cussing them, the frequency analysis revealing a risk of 
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pathology development of individual tests from the target 
level in patients’ population was used.
As Table 4 shows, 30-100% changes of the urine syn-
drome parameters and 39-93% changes of the intoxicati-
on syndrome parameters were registered in patients in the 
acute stage of chronic cystitis; positive bacteriologic tests 
were revealed in 90-91% of cases, sterile samples – in 
9% of cases; variations of routine hematological findings 
of inflammation markers amounted to 3-25%, which cor-
responded to pathological findings of the 75% of grouped 
cellular, 67% of humoral, 50% of phagocytic and cytoki-
ne parameters. 
Table 1. Clinical Laboratory Status of Patients with Chronic Cystitis in the Relapse Stage: Formalized Rank Evaluation of Groups 
with Various Immunologic Risks
Parameters Patients of no-risk group (26) Patients of risk group (156)
Patients of increased risk 
group (18)
Clinical parameters
Frequent urination 26/100/1* 156/100/1* 18/100/1*
Urogenital incontinence 5/19/3* 131/84/1* ** 16/89/1* **
Lower abdominal pains 23/88/1* 145/93/1* 18/100/1*
Cloudy urine 26/100/1* 156/100/1* 18/100/1*
Foul-smelling urine 14/53/2* 150/90/1* ** 18/100/1* **
Subfebrile condition 9/35/2* 61/39/2* 8/44/2*
Intoxication 6/23/3* 61/39/2* ** 10/56/2* **
Leukocyturia 15/58/2* 110/71/1* 13/72/1*
Hematuria 5/19/3* 47/30/3* 6/33/2*
% of deviation from the norm 55.0 72.3** 77.1* **
Bacteriologic parameters 
Bacteriuria 24/91/1* 142/91/1* ** 17/94/1* **
E. coli 18/62/2  * 140/90/1* 16/89/1*
Other GN flora 2/8/3 2/1/3 1/6/3
Sterile samples 3/8/3 14/9/3 1/6/3
% of deviations from the norm 91.0 91.0 94.0
Routine hematologic parameters 
Leukocytosis 4/15/3 31/20/3* 6/33/2* **
Lymphopenia 1/4/3 14/9/3 4/22/3* **
Neutrophilia 5/20/3* 29/19/3* 4/22/3*
Monocytosis 2/8/3 5/3/3 4/22/2*
Accelerated ESR 1/4/3 4/3/3 1/6/3
% of deviations from the norm 10.2 16.6 21.0
Grouped immunologic parameters 
By mean values 
Total 50/2* 62/2* 73/1* **
Cellular 83/1* 75/1* 100/1* **
Humoral 67/1* 67/1* 67/1*
Phagocytic 50/2* 50/2* 50/2*
Cytokine 17/3* 50/2 * ** 50/2* **
By frequency analysis 
Resulting 23/3* 39/2* 53/2* **
Σ of ranks 54/III 46/II 39/I
% of deviations from the norm 48.3 57.2 65.5**
Mean % of deviations 43.5 56.6 59.0**
Note: Σ – sum of ranks (a number of patients/ % of deviations from the norm/rank); 1 – reliable significant (deviations > 66% of pa-
rameters), 2 – reliable mean (33-66%), 3 – insignificant (<33%); *- validity of deviations from the norm when P<0.05; **- validity 
of deviations from the parameters of patients of the no-risk group; the rest see above.
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Efficacy of the conventional therapy of chronic cystitis
Significant normalization of clinical parameters was achie-
ved in patients 7-10 days after the administered standard 
treatment. Frequent urination, urge urine incontinence, 
cloudy foul-smelling urine, lower abdominal pains, leuko-
cyturia, terminal hematuria were registered in 16-21% of 
cases, and subfebrile condition, intoxication were comple-
tely eliminated. The total percentage of deviations from the 
norm before and after treatment made up 72.7 and 11.1%, 
with the 6.5-time difference. Moreover, bacteremia in the 
urine with E. coli monoculturing decreased from 90-91% 
to 25%, and the number of sterile samples consistently in-
creased to 75%; on average, the normalizing dynamics of 
bacteriologic parameters increased 3.6 times.
Leukocytosis, lymphopenia, neutrophilia persisted in 
16% of patients; monocytosis and accelerated ESR were 
registered in isolated cases with unreliable 1.2-time vari-
ations of hematologic parameters.
The following fact should be taken into consideration 
when assessing the variations of immunologic parame-
ters: 7-10 days appeared to be a non-optimal period of 
examination, which was evidently insufficient to deve-
lop rehabilitation mechanisms. From this perspective, 
the parameters revealing regularities of reaction in pa-
tients with cystitis were grouped in total and by separate 
components of the immune system. Resulting norma-
lizing immunotropic effect of the conventional therapy 
of chronic cystitis in the relapse stage was low, since, 
in terms of quantity, the number of the modified tests 
Table 2. Actual Deviations of Laboratory Parameters from the Standard Level in Patients with Cystitis
Parameters Group 1 Group 2 Group 3 Group 4
No-risk 
group
Risk 
group
Increased 
risk group
Risk 
group
Increased 
risk group
Increased 
risk group
Cellular parameters 
Т - - - - -
Т-helpers + - - - - -
Т-cytotoxic - - - - +
Т-regulatory + - -
Т-activated - - - + + +
NKT-dependent + - + + +
NKregulatory + + + + + +
NKcytotoxic + + +
Humoral parameters
В + + + + +
IgM + + + + +
IgG + + + -
IgA - - + + -
Circulating immune complexes (CIC) + - + + + +
Medium weight molecules (MWM) + + +
Phagocytic parameters 
CD11b + -
CD18
Phagocytic index (PhI) + - - + + -
Phagocytic number (PhN) + - - + + -
Nitro Blue Tetrozolium spontaneous (NBTspont) - - - - -
Nitro Blue Tetrozolium activated (NBTactiv) - - - -
Cytokine parameters 
IL2 -
IL4 - - -
IL6 + + + +
IL8 + + + + +
IL10
Tumor necrosis factor (TNF) + + +
Note: +/- reliable deviations of parameters from the norm, Р< 0.05.
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Table 3. Interpretation of the Immune Status Depending on the Risk Group in Patients with Immune Cystitis
Disorder Group of risk
Grouped parameters Sum of 
ranks
Devia-
tions
Key parameters
C H Ph Cy Т:В:N FISD
Acute cystitis Risk group 1 1 2 3 7 IV 2:1:3 Tcytotoxuc*3IgM*3MWM*2
Chronic 
cystitis in the 
relapse stage
No-risk group 2 1 2 3 8 V IgM+3NBTspont-2Т-3
Risk group 1 1 2 2 6 III 2:2:2 Tcytotoxic+3 IgA-2 IL6+
Increased risk 
group 1 1 1 2 5 II NKcytotoxic
+
3Tcytotoxic+3Тhelpers+3
Chronic cysti-
tis combined 
with chronic 
pyelonephritis 
Increased risk 
group 1 1 1 1 4 I 2:2:2 CIC
*
3Т
*
3PhN-3
Chronic cysti-
tis combined 
with chronic 
salpingo-oo-
phoritis
Increased risk 
group 1 1 1 1 4 I 1:2:3 Tregulatory
*
2NKregulatory*2MWM*3
Note: 1, 2 ranks – reliable deviations from the norm level in 66-100% and 33-66% of patients, 3 – unreliable - < 33%; C, H, Ph, 
Cy – cellular, humoral, phagocytic, cytokine parameters; T:B:N – distribution of key tests modifications into T-, B-dependent and 
Non-specified links of the immunity in ranks. 
Table 4. Clinical Laboratory Effects of Differentiated Immunotherapy of Chronic Cystitis in 7-10 Days – 3-4 Months
Parameter
Variants of treatment
Back-
ground
Conven-
tional 
therapy
+Kf +Sl +If +Gl +Sl+If
Conven-
tional 
therapy
Sl+If
7-10 days 3-4 months
% of clinical parameters
Frequent urination 100** 16* ** 16* ** 0* *** 8* *** 12* 0* *** 75* ** 24* ** ***
Urge urine inconti-
nence 83
** 16* ** 12* 8* 0* *** 0* *** 0* *** 50* ** 15* ***
Lower abdominal pains 93** 12* 12* 8* 8* 4* 4* 65* ** 10* ***
Cloudy urine 100** 16* ** 8* 0* *** 0* *** 4* 0* *** 75* ** 0* ***
Foul-smelling urine 96** 12* 0* 0* 0* 0* 0* 75* ** 0* ***
Subfebrile condition 39** 0* 0* 0* 0* 0* 0* 25* ** 0* ***
Intoxication 39** 0* 0* 0* 0* 0* 0* 30* ** 0* ***
Leukocyturia 71** 12* 4 * 4* 0* 0* 0* 50* ** 0* ***
Hematuria 30** 16 0* 0* *** 0* *** 0* *** 0* *** 35** 0 * ***
% of bacteriological parameters
Bacterimia 91** 25* ** 4* *** 4* *** 4* *** 0 * *** 0* *** 9/45* ** 25*  ** ***
E.coli 90** 25* ** 4* *** 4* *** 4* *** 4* *** 0* *** 9/45* ** 25* ** ***
Unidentified GN flora 3 6 0 0 0 0 0 0 0
Sterile samples 19 75* ** 92* ** *** 96* ** *** 92* ** *** 96* ** *** 96* ** *** 9/45* ** 75* ** ***
% of routine hematologic parameters
Leukocytosis 20** 16** 0* *** 0* *** 0* *** 0* *** 0* *** 25** 0 * ***
Lymphopenia 9 16** 12 16** 8 6 0*** 19** 10
Research Results in Pharmacology 4(4): 65–77 71
Parameter
Variants of treatment
Back-
ground
Conven-
tional 
therapy
+Kf +Sl +If +Gl +Sl+If
Conven-
tional 
therapy
Sl+If
7-10 days 3-4 months
Neutrophilia 19** 16** 4 0* *** 4 12 0* *** 15 0*
Monocytosis 2 12 4 8 12 20** 20** 0 25* ** ***
ESR 1 8 0 4 4 0 0 5 0
% of grouped immunologic parameters
Total 62 62 46* *** 31* *** 38* *** 50* 27* *** 75 31* ***
Cellular 75 63 38* *** 50* 13* *** 50* 25* *** 83 25* ***
Humoral 67 67 50* *** 67* 50* *** 67 17* *** 67 17* ***
Phagocytic 50 50 17* *** 0* *** 13* *** 0* *** 17* *** 67* 33* ***
Cytokine 50 67* 83* *** 0* *** 83* *** 83*  *** 50* *** 67* 33* ***
% of deviations from 
the norm 61.8 61.8 46.8 29.6 39.5 50.0 7.1 45.6 13.0
Note: *- deviations from the background, ** - deviations from the norm, *** - deviations from the conventional therapy, Р<0.05.
Table 4. (continued)
was reported to be equal to the initial one  – 16 and 16 
(61.5%). 
In terms of quality, the treated patients manifested 
suppression of the cellular immunity, accumulation of 
B-cells, dysimmunoglobulinemia M, G, A, a reduced ab-
sorptive and metabolic capacity of phagocytes, disbalan-
ce of pro- and anti-inflammatory cytokines. 
As a result, implementing the conventional non-immu-
notropic treatment of chronic cystitis in the early relapse 
stage, on 7-10 days, promoted the high-grade remission of 
the disease with retaining the clinical symptoms in 11.1% 
of cases, modified bacteriological parameters in 25% of 
cases, routine hematologic parameters in 13.6% of cases, 
immunologic parameters in 61.8% of cases. 
Efficacy of the local immunotherapy of chronic cystitis 
in the relapse stage with application of kipferon and 
superlimf
Kipferon – a complex of immune globulins of the main 
classes in combination with recombinant human interfe-
ron – was selected as a local modulator. It is usually ap-
plied in immunodeficient conditions, supperative-inflam-
matory processes in urogenital organs, etc. (Strel’tsova et 
al. 2013).
A complex treatment with kipferon in patients suffe-
ring from the given disorder, who had 10-30% of modi-
fied clinical parameters before treatment, provided the 
following results: subfebrile condition and general in-
toxication were completely eliminated; lower abdominal 
pains, foul-smelling urine, leukocyturia remained in 12% 
of cases; and frequent urination, hematuria remained in 
16% of cases. In addition, a period of hospitalization sig-
nificantly reduced with using kipferon –
from 6.0+-0.5 days to 4.9+-1.0 days, Р < 0.05. 
Additional administration of Kf to patients with the 
given disorder resulted in the reduction of the initial bac-
teriuria and E. coli culturing from 91-90% to 25%, and an 
increase in urine sterility from 9 to 92%. 
Dynamics of routine hematologic parameters of in-
flammation tended to normalize, but appeared insignifi-
cant.
The identification of the final normalizing immunot-
ropic effect from the traditional therapy combined with 
kipferon provided reliable, but not considerable effect, 
since the proportion of parameter deviation decreased 
from 61.5 to 46.8%.
In terms of quality, the modulator provided accumulati-
on of T cytotoxic suppressors combined with a decreased 
level of main populations of killer cells, with stimulation 
of the B-cells content, immune globulins of two classes 
against the background of phagocytosis inactivity, hyper-
production of anti-inflammatory interleukins 2, 6, 8 and a 
decrease in tumor necrosis factor alpha (TNF-alpha).
Superlimf is a natural complex of immune peptides 
with the activity of certain cytokines. The preparation 
stimulates leukocytes and phagocytosis, tissue regenerati-
on, and reduces intensity of inflammation. It is applied in 
treatment of secondary immunodeficient conditions, sup-
perative wounds, and trophic ulcers (Daniels et al. 2018, 
Neymark et al. 2016).
As Table 4 demonstrates, a clinical effect of superlimf 
in combination with the conventional therapy of cystitis 
proved to be rather significant, since 6 out of 9 studied 
parameters – frequent urination, cloudy urine, foul-smel-
ling urine, subfebrile condition, intoxication, hematuria – 
were normalized to zero. Leukocyturia persisted in 4% of 
cases, urge urine incontinence and lower abdominal pains 
persisted in 8% of cases. The average proportion of de-
viations of clinical parameters from the norm amounted 
Kulintsova YV et al.: Immunotherapy in the treatment of  chronic cystitis72
to 2.2%, which was reported to be 33 times lower than 
before the treatment – 72.7%. This considerable effect 
of the complex treatment resulted in a reduced period of 
hospitalization of patients with the disorder in question to 
4.5 +-1.0 days.
The effect of superlimf immunotherapy on bacteriolo-
gic parameters of patients was similarly significant, indi-
cating a decrease in the initial bacteriuria, mainly with E. 
coli monoculture, from 90-91% to 4% (a 22.8-time devia-
tion); the number of sterile samples accordingly increased 
from 9 to 96%, a 10-time increase. 
Normalization of the routine hematologic parameters 
of inflammation was less pronounced. Leukocytosis per-
sisted in 16% of cases, neutrophilia – in 8% of cases, mo-
nocytosis – in 4% of cases; limphopenia and ESR were 
eliminated to 0%. However, it should be highlighted that 
the initial deviation of these parameters from the norm 
was low, from 1 to 20%. Nevertheless, in average, the per-
centage of deviations from the norm was insignificant and 
amounted to 5.6%.
Nonetheless, the capacity of superlimf to cause qua-
litative deviations of immunologic parameters from the 
initial level was relevant – 6 tests out of 26 (21.9%). As a 
result, the deviations of the parameters from the norm – 
29.6% - were statistically significant, Р<0.05.
The abovementioned qualitative changes were com-
bined with disbalance of cellular parameters, standard 
reaction of the humoral arm in the form of an increased 
concentration of B-lymphocytes, IgM, IgG, a decreased 
number of the immunoglobulin A with no variations of 
phagocytic and cytokine parameters. 
Special attention should be paid to the fact that efficacy 
of the local immunomodulator effect firstly on the clinical 
and bacteriologic, and then – on routine hematologic and 
immunologic parameters, reduced gradually.
Thus, immunotherapy with additional application of 
the local immunity modulators kipferon and superlimf in 
patients with chronic cystitis decreased the proportion of 
deviations from the norm:
– of clinical parameters – 12.5 and 32.9 times (from 
72.3 to 5.8 and 2.2%, respectively);
– of bacteriologic parameters – 17.1 and 22.7 times 
(from 90.7 to 5.3 and 4.0%);
– of routine hematologic parameters – 3.5 and 3.0 
times (from 16.6 to 4.8 and 5.6%);
– of immunologic parameters – 5.5 and 6.2 times 
(from 55.6 to 10.2 and 9.0%).
Overall, high average clinical laboratory normalizing 
efficacy of one conventional treatment – 2.4 times –was 
exceeded 5.5 and 6.2 times.
Efficacy of systemic immunotherapy of chronic cystitis 
with application of imunofan and galavit
Imunofan is a synthetic thymomimetic drug, hexapeptide 
with immunoregulating, detoxic, hepaprotective, metabo-
lic characteristics, capable of inactivating lipid peroxida-
tion, activating the antioxidant system, as well as cellular 
and humoral immunity, and suppressing excessive in-
flammation (Jung et al. 2018, Keagy 2018).
The performed study demonstrated that if additionally 
administered to patients resulted in the normalization of 5 
out of 6 symptoms of the urine syndrome: urge urine in-
continence, cloudy and foul-smelling urine, leukocyturia 
and hematuria. However, frequent urination persisted in 
8% of patients. Two symptoms characterizing the intoxi-
cation syndrome – subfebrile condition and general malai-
se – were completely eliminated. Frequent urination and 
lower abdominal pains were eventually detected in 8% of 
cases. The duration of hospitalization was 5.1±0.9 days. 
The examination of the urine bacteriologic parameters 
showed a decrease in the initial bacteriuria and pathog-
nomonic E. coli culturing from 90-91% to 4%. Thus, the 
number of sterile samples increased from 9 to 92%.
The deviation of routine hematologic markers of in-
flammation from the baseline parameters was insignifi-
cant, but tended to decrease. For example, the baseline 
parameters of leukocytosis fell from 20% to 8%, and the 
baseline parameters of neutrophilia fell from 19% to 12%. 
Monocytosis, accelerated ESR were detected in isolated 
cases before and after the treatment. On average, the total 
proportion of hematologic parameters in treated patients 
significantly decreased from 16.6 to 4.9% (3.4-time dif-
ference). 
The deviation of immunologic parameters from the 
baseline ones under the influence of the conventional 
therapy combined with imunofan modulator therapy sig-
nificantly changed in 34.6% of tests; the corresponding 
parameter made up 61.8 and 39.5% of the norm, Р <0.05. 
It the patients of this group discharged from the hos-
pital, inactivity of T-dependent parameters, accumulation 
of B-cells, CIC, a decrease in  IgA formation, occasional 
accumulation of cells with CD11b marker in combination 
with IL6, IL8 hyperproduction, IL4 and TNF-alpha hypo-
formation were detected. 
Galavit was selected as the second modulator of 
systemic immunity. This preparation - aminodioxote-
trahydrophtalasinedione sodium – is characterized by 
anti-inflammatory, antioxidant, immunomodulating 
properties, regulates pro- and anti-inflammatory cyto-
kines, activates macrophages, granulocytes, natural kil-
lers, interferons and is applied in infectious, inflamma-
tory, urogenital pathologies of pelvic organs (Dellis and 
Papatsoris 2018, Lai et al. 2014).
As Table 4 demonstrates, application of galavit provi-
ded a manifold decrease in initially prevailing (in 83 out 
of 100% of cases) major symptoms of the urine syndro-
me – frequent urination, urge urine incontinence, clau-
dy and foul-smelling urine, lower abdominal pains – to 
0-4-12%. Moreover, subfebrile condition, intoxication, 
leukocyturia, hematuria decreased from 30-71% to zero. 
On average, the proportion of deviation of clinical para-
meters from the norm was 72.3 and 2.2%. The duration 
of hospitalization of patients with chronic cystitis in the 
relapse stage treated in complex with galavit was 6.0±0.5 
and 4.3±0.8 days, Р <0.05.
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Highly positive results were obtained when studying 
dynamics of bacteriologic parameters in patients.The ba-
seline parameters of bacteriuria decreased from 91% to 
zero, and E. coli culturing – from 90% to 4%. With that,, 
the proportion of sterile urine samples increased from 9 
to 96%.
In 5 investigated hematologic parameters of leukocy-
tosis inflammation, the proportion of detection decreased 
from 20 to 6%. Though the variations of other laborato-
ry parameters were not so impressive, the proportion of 
deviations of parameters from the norm decreased from 
16.6% to 5.1% on average. 
An immunotropic effect of galavit in a frontal descrip-
tive analysis was the following: mobile effect of the pre-
paration was expressed in relevant deviation of the para-
meters from the baseline – by 42.3%. With that, 50% of 
tests deviated from the norm. The analysis of qualitative 
peculiarities stated the excess amount of T cytotoxic, NK, 
the deficiency of T-helpers and T-regulatory, irritation of 
B-link by Ig of two main classes, MWM and cytokine 
parameters – IL2, 4, 6, 8 combined with insufficiency of 
anti-inflammatory TNF.
Thus, immunotherapy with additional application of 
the local immunity modulators imunofan and galavit in 
patients with chronic cystitis decreased the proportion of 
deviations from the norm 7-10 days later:
– of clinical parameters – 40.2 and 32.9 times (from 
72.3 to 1.8 and 2.2%, respectively);
– of bacteriologic parameters – 17.1 and 33.6 times 
(from 90.7 to 5.3 and 2.7%);
– of routine hematologic parameters – 3.4 and 3.2 
times (from 16.6 to 4.9 and 5.1%);
– of immunologic parameters – 1.6 and 1.2 times 
(from 61.6 to 39.3 and 50.0%).
Overall, high average clinical laboratory normalizing 
efficacy of non-immunotropic treatment – 2.4 times –was 
exceeded 5.2 and 4.3 times.
Efficacy of the combined immunotherapy of chronic 
cystitis with application of superlimf and imunofan
A preliminary study demonstrated high capacity of the 
conventional non-immunotropic treatment of chronic 
cystitis in the relapse period to correct clinical and bac-
teriologic parameters, but not routine hematologic and 
immunologic ones. Additional administration of local and 
systemic immunostomulators relevantly resulted in the 
normalization of not only clinical and bacteriologic, but 
also hematologic and immunologic parameters. That is 
why some patients were grouped to be treated complexly 
with  Sl with If (Gyaurgiyev et al. 2015, Kapral et al. 
2018, Tyuzikov et al. 2018).
The data obtained indicated a practically limited cli-
nical effect of the combined immunotherapy. Complete 
elimination of frequent urination, cloudy and foul-smel-
ling urine (the baseline parameters 100 – 96%), urge 
urine incontinence (the baseline parameters – 83%), sub-
febrile condition and intoxication (the baseline parame-
ters – 39%), terminal hematuria (the baseline parameters 
– 30%) was obtained in all patients. Only 4% of patients 
treated with a complex therapy still had lower abdominal 
pains and leukocyturia. 
The bacteriological data demonstrated that urine bac-
teriuria with E. coli monoculturing persisted only in one 
patient of 25; accordinly, the number f sterile samples of 
diagnostic material increased from 9% to 96%.
Initially low detection of hematologic markers of in-
flammation – leukocytosis, limphopenia, neutrophilia, ac-
celerated ESR – decreased after application of two modu-
lators to isolated cases; monocytosis was only registered 
in 20% of cases after the treatment. 
A mobile effect of the combination of immunocorrec-
tors on patients’ immunologic parameters was significant 
compared to the baseline and included 14 parameters – 
54% of all investigated tests. Correspondingly, the norma-
lizing effect of the modulators turned out to be maximal. 
As a result, the cellular and humoral parameters returned 
to normal, whwereas the phagocytic and cytokine ones 
did not.
Overall, general proportion of the modified clinical la-
boratory parameters decreased 8.2 times 7-10 days after 
administration of the complex of correctors; which was 
significantly higher than the effect of one conventional 
treatment – 2.4 times.
Efficacy of the conventional treatment and combined 
immunotherapy of chronic cystitis with superlimf and 
imunofan in 3-4 months
As Table 4 demonstrates, the proportion of the modi-
fied parameters in the group of the controlled treatment 
were as follows (the baseline – after 7-10 days – after 
3-4 months): the percentage of frequent urination was 
100-16-75%, of urine incontinence – 83-16-50%, of pain 
syndrome – 93-12-65%, of cloudy and foul smelling urine 
– (100-96%) – (16-12%) – 75%. Completely eliminated 
subfebrile condition and intoxication increased to 25-30% 
in the extended period, leukocyturia and hematuria grew 
from 12-16 to 50-35%. 
Similar parameters were obtained when assessing vari-
ations of bacteriologic laboratory parameters. Thus, bac-
teriuria and E. coli culturing increased from the baseline 
parameters (90-91%) to 25% obtained after 7-10 days and 
to 45% after 3-4 months. Variations of sterile samples 
amounted to 9% – 75% – 45%, respectively. Leukocyto-
sis, limphopenia and neutrophilia were registered within 
the limits 25%-19%-15%. Overall, on average general 
frequency of deviations of bacteriologic, routine, hema-
tologic tests from the norm approached to the baseline 
parameters observed before treatment.
It should be noted that an immunotropic effect of 
the conventional treatment of chronic cystitis after 3-4 
months was as insignificant as at the earlier period. Appa-
rently, assessment of these reactions after 7-10 days was 
too early, and after 3-4 months – too late. For example, 
a normalizing effect of the conventional treatment at the 
later period was sufficiently low, since relevant deviati-
on of 17 clinical laboratory parameters out of 26 studied 
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parameters (65.4%) was was recorded, compared to the 
baseline – 16 (61.5%) - and 7-10 days after treatment – 16 
(61.5%). 
Due to the fact that the positive clinico-bacteriological 
effect of the conventional therapy wore off 3-4 months 
after the treatment, disease recurrence was observed (Ge-
lashvili et al. 2014, Kurilovich 2017).
Analysis of efficacy of the immunotherapy with the 
combination of superlimf and imunofan in patients with 
acute cystitis in the relapse period demonstrated that after 
3-4 months the deviation from the norm was registered 
only in one out of 9 clinical parameters.
Practically similar results were obtained when investi-
gating patients’ bacteriologic parameters. Application of 
the combination Sl+If resulted in a decrease in systemic 
bacteremia, E. coli culturing from 91-90% to 45% and 
25%, and an increase in the proportion of sterile samples 
from 9% to 45% and 75% compared to the baseline and 
the level of one conventional treatment after 3-4 months.
Studying the variations of hematologic evidences of 
inflammation revealed certain monotony in this period. 
However, mean values of the deviations – 12.8 and 7% – 
tended to normalize. 
The results of immunotropic effect of the conventio-
nal treatment combined with modulators appeared to be 
insignificant after 3-4 months, resulting in the relevant 
variations of 6 tests out of 26 (21.3%) compared to the 
parameters obtained after 7-10 days – 14 tests (54%). 
However, resulting mean values of the clinical labora-
tory parameters of patients from the control and expe-
rimental groups made up 45.6% and 13.0% of the norm 
at the later period. Therefore, a normalizing effect of the 
immunotherapy at the later period was lower than that in 
the acute period, but still significant to prevent relapse of 
the disease. 
Key targets of the differentiated immunotherapy of 
chronic cystitis
The key components of target formulas of individual 
immunotropic preparations were defined, and their indi-
viduality was stated: depending on the set and the order 
of arrangement, on the vector and degree of intensity of 
deviations (Table 5). Thus, FTI (the formula of targets of 
immunocorrection) of one conventional treatment inclu-
ded NBTspont+3 NKcytotoxic-2 TNF+3. The impact of the con-
ventional treatment combined with Kf distributed into 
TNF, CIC, Tactiv lymphocytes; combined with Sl – into 
IL4, Tcells, PhI; combined with If – into T-lymphocytes, 
Thelpers, MWM; combined with Gl – into NBTspont, NBTac-
tive, IL4; and combined with Sl+If – into subpopulations 
of natural killers.
The determined individuality of mechanisms of action 
of the complex treatment depended on the immunotropic 
Table 5. Signal Parameters and Their Correlative Links in Patients with Chronic Cystitis after Differentiated Treatment
Key formulas
Therapeutical variations
Conventional 
therapy +Kf +Sl +If +Gl +Sl+If
After 7-10 days
FISDbaseline Tcytotoxic+3  IgA-2  IL6+2
FTI
NBTspont +3
NKcytotoxic-2
TNF+3
TNF-3
CIC-2
Tactiv+2
IL4+3
Т+2
PhI+2
Т+3
Thelpers+3 
MWM-3
NBTspont+2
NBTactiv+3 
IL4+3
NKT-depen+3
NKcytotoxic+3
NKregulat+3
FTIprop
Т+2
TNF-3
IL4+3
PhN+3
PhI+2
IL4+3
Tcytotoxic+3
Thelpers+3
Tregulat+3
IgA+3
NKcytotoxic+2
TNF-3
Т+3
Tactiv+3
NBTactiv+2
FISDim
IgG+3
СD18+3
PhN+3
NKregulat+3
IL2+2
IgG+3
NKcytotoxic+3
Tcytotixic+3
IgG+3
CD11в+3
В+3
IL8+2
Tcytotoxic+3
IgM+3
IgG+3
Tactiv+2
В+2
CD11в+3
After 3-4 months
FTI
NKregulat-2
IL10+2
Т-2
Tactiv+3
IgG-3
IL6-2
FTIprop
Т+3
Thelpers+3
Tactiv+3
FISDim
NKcytotoxic-3
IgM+2
Tregulat-2
IgA-2
Tactiv+2
IgG+3
Note: *- deviations from the background, ** - deviations from the norm, *** - deviations from the conventional therapy, Р<0.05.
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properties of the conventional therapy and properties 
of correctors. A “proper” effect of modulators was de-
tected using a special mathematic method (Zemskov et 
al. 2008). For example, FTI of the complex of the basic 
therapy combined with Gl included NBTspont+2 NBTactiv+3 
IL4+3, and one modulator (FTIprop) – absolutely different 
parameters - IgA+3 NKcytotoxic+2 TNF-3.
Correlation of signal parameters of the immune disor-
ders in the treatment of chronic cystitis
Strong correlative associations of immunologic parame-
ters with other parameters of laboratory status marked 
tension in the immune system with the following inter-
pretation: the more associations are revealed, the higher 
is the optimality of functioning and, consequently, the ef-
ficacy of treatment (Zemskov et al. 2016).
The data obtained evidenced that coordinated associa-
tion of laboratory parameters in patients with cystitis was 
lower than that in healthy people; the number of strong 
associations of basic parameters of FISD during the treat-
ment increased compared with the baseline; and in case of 
additional application of modulators – even compared to 
application of only conventional preparations. Moreover, 
various immunotropic preparations resulted in differenti-
ated modulation of tension in the immune system (Malik 
et al. 2018).
Detection of significant associations between immuno-
logic FISD tests (Thelpers+3 IgA-2IL6+2) and metabolic stress 
parameters in patients was especially important. Accu-
mulation of T cytotoxic suppressors positively correlated 
with the primary product of lipid and protein oxidation 
– diene conjugates, and an increased concentration in an-
ti-inflammatory IL6 negatively correlated with enzymatic 
and non-enzymatic factors (vitamin E and systemic thiols) 
of an antioxidant defense. The above makes it possible to 
assume the presence of a certain hypothetic link between 
immunologic and metabolic parameters in patients with 
chronic cystitis. 
Laboratory parameters to select optimal immunothe-
rapeutic options of chronic cystitis
An inversion analysis of calculated FTI was applied for 
tailor-made selection of optimal modulators (Zemskov 
et al. 2016, Zemskov et al. 2017). The principle of the 
method is as follows: if, for example, according to FTI – 
NBTspont +2 NBTactiv+3 IL4+3 – galavit determines activation 
of the NBTspont and NBTactiv of 2-3 degree and the limited 
formation of IL4, thus, this modulator will be efficient in 
the reduction of the indicated degree of indicators. 
It was stated that one conventional treatment of patients 
with chronic cystitis may be administered when NBTspont 
> 14.1%, NKcytotoxic – 0.06-0.08 *109/l, TNF > 0.32 pcg/
ml; kipferon – TNF<0.06 pcg/ml, CIC – 9.1-18.3 RU, Tac-
tiv-0.16-0.82*109/l; superlimf – IL4>32.6 pcg/ml, Т -2.0-
2.3 *109/l, PhI – 96.6-129,7%; imunofan – Т>2.5*109/l, 
Тhelper-1.46-1.8*109/l , MWM<1.9 RU; galavit – NBTspont 
-11.3-14.1%, NBTactiv> 37.5%, IL4 > 32.6 pcg/ml; super-
limf+ imunofan NKT >0.9*109/l, NKcytotoxic> 0.2*109/l, 
NKregulat>0.59*109/l.
Comparative efficacy of differentiated immunothera-
py of chronic cystitis in formalized evaluation
The results of the overall evaluation of the clinical labo-
ratory efficacy of differentiated immunotherapy are given 
in Table 4.
The data obtained evidenced that various immunothe-
rapeutic options of chronic cystitis cause a differentiated 
action on the patients’ clinical, bacteriologic, hematologic 
and immunologic parameters. As a result, the overall de-
creasing range of treatment efficacy after 7-10 days was 
as follows:  Sl+If, Sl, Kf, If, Gl, ConvTh (conventional 
therapy); after 3-4 months – ConvTh, ConvTh+Sl+If.
Conclusions
1. Chronic cystitis in the relapse stage is accompanied by 
the underlying formation of immunopathologic syn-
dromes; which makes it possible to include the given 
patients into the risk group. This is accompanied by the 
development of typical clinical symptoms in 72.3% of 
cases, deviation of bacteriologic parameters in 90.7% 
of cases, deviation of routine hematologic parameters 
in 16.6% of cases, deviation of immunologic param-
eters in 57.8% of cases. The key components of the 
immune disorders in the presence of disbalance of the 
primary and secondary, enzymatic and non-enzymatic 
mechanisms of oxidative stress are formalized in the 
formula. 
2. Conventional non-immunotropic therapy of chronic 
cystitis in the relapse stage results in a significant de-
crease in deviations from the norm after 7-10 days, as 
regards the incidence:
– of clinical symptoms – from 72.3 to 11.1%, (6.5 
times);
− of biological parameters markers – from 90.7 to 
25.0% (3.6 times);
− of routine hematologic parameters – 16.6 and 12.8% 
(insignificantly);
− of immunologic parameters – 61.8-61.8% (insig-
nificantly). 
The positive clinical bacteriologic effect of the con-
ventional treatment completely wears off after 3-4 
months; which results in the relapse of the disease.
3. Additional immunotherapy with modulators of the lo-
cal immunity – kipferon and superlimf – administered 
to patients with chronic cystitis decreases the propor-
tion of the deviations from the norm after 7-10 days:
− of clinical parameters - 12.5 and 32.9 times;
− of bacteriologic parameters – 17.1 and 22.7;
− of routine hematologic parameters – 3.5 and 3.0 
times;
− of immunologic parameters – 5.5 and 6.2 times. 
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Overall, high average clinical laboratory normalizing 
efficacy of one conventional treatment – 2.4 times – 
was exceeded 5.6 and 6.2 times.
4. Additional immunotherapy with modulators of the lo-
cal immunity – imunofan and galavit – administered to 
patients with chronic cystitis decreases the proportion 
of the deviations from the norm after  7-10 days:
− of clinical parameters - 40.2 and 32.9 times;
− of bacteriologic parameters – 17.1 and 33.6 times;
− of routine hematologic parameters – 3.4 and 3.2 
times;
− of immunologic parameters – 1.6 and 1.2 times. 
Overall,high average clinical laboratory normalizing 
activity of non-immunotropic treatment – 2.4 times 
– was exceeded 3.4 and 2.2 times.
5. A normalizing clinical laboratory effect of the com-
bined immunotherapy of chronic cystitis in the relapse 
stage with superlimf and imunofan is reported to be 
lower at the later period – after 3-4 months - compared 
with the parameters obtained after 7-10 days. Howev-
er, this effect is sufficient enough to prevent the relapse 
of the disease. On average, the proportion of deviations 
from the norm of all tests at the indicated periods de-
creased from 53.8% to 26.1% and 14.2%, the differ-
ence being 2.1-3.8 times. 
6. Six options of the immunotherapy of chronic cystitis 
in the relapse stage implement various mechanisms of 
action on patients’clinical-laboratory parameters, their 
correlative links dependant on the conventional treat-
ment given, the types of modulators and their combina-
tions, the duration of examining patients, the following 
range of activity of the drugs is offered – Sl+If, Sl, Kf, 
If, Gl, ConvTh.
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